Toll like receptors: an overview

  • Authors

    • Gopi Shah Charotar University Of Science And Technology, RPCP, CHARUSAT, CHANGA
    • Bharat Patel Charotar University Of Science And Technology, RPCP, CHARUSAT, CHANGA
    • Mehul Chorawala K.B.Institute of Pharmaceutical Education and Research, Kadi University, Gandhinagar
    2014-07-19
    https://doi.org/10.14419/ijpt.v2i2.3027

  • Abstract

    Toll like receptors (tlrs) are first identified in drosophila and recognise pathogen associated molecular patterns (pamps) expressed by various micro-organisms and are also known as pattern recognition receptors (prrs). pamps are important for both innate and adaptive response. Among all tlrs, tlr1, tlr2, tlr3 and tlr4 are expressed on plasma membrane while tlr3, tlr7, tlr8 and tlr9 are expressed intracellularly. Downstream signalling of tlr activation involves expression of numerous cytokines, chemokines and co-stimulatory molecules such as irak, traf, tirap and sarm via myd88 dependant and independent pathway. This is a key step for both innate and adaptive immunity. tlrs play an important role in pathogenesis of various diseases including infectious diseases, autoimmune diseases, neurodegenerative diseases, lung disease, skin disease and cancer. Most studied tlrs are tlr2, tlr4, tlr3 and tlr9. In brief, this review emphasizes on types of tlr, their ligands, location, signalling pathway and role in various diseases.

    Keywords: Toll like Receptors, Pathogen Molecular Patterns, Myd88 Pathway, Adaptor Proteins.

  • References

    1. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. (2001). Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol; 167:1609-1616.
    2. Akira S, Takeda K. (2004).Toll-like receptor signalling. Nat Rev Immunol; 4: 499–511.
    3. Akira S, Yamamoto M, Takeda K. (2003) Role of adapters in Toll-like receptor signalling. Biochem Soc Trans; 31(3):637–42.
    4. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature; 413: 732–738.
    5. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature; 413:732 8.
    6. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. (2001). Recognition of double stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature; 413:732-738.
    7. Arch RH, Gedrich RW, Thompson CB. (1998). Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death. Genes Dev; 12:2821–30.
    8. Backhed F, Rokbi B, Torstensson E, Zhao Y, Nilsson C, Seguin D, Normark S, Buchan AM, Richter-Dahlfors A. (2003). Gastric mucosal recognition of Helicobacter pylori is independent of Toll-like receptor 4. J Infect Dis187:829-836.
    9. Belinda LW, Wei WX, Hanh BT, Lei LX, Bow H, Ling DJ. (2008). SARM: a novel Toll-like receptor adaptor, is functionally conserved from arthropod to human. Mol Immunol; 45:1732–42.
    10. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR. (2005). The molecular structure of the Toll-like receptor 3 ligand binding domain. Proc Natl Acad Sci; 102:10976-10980..
    11. Beutler B. (2005). The Toll-like receptors: analysis by forward genetic methods. Immunogenetics; 57:385–92..
    12. Bonnard M, Mirtsos C, Suzuki S, Graham K, Huang J, Ng M, et al. (2000). Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-κB-dependent gene transcription. EMBO J; 19: 4976–85.
    13. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. (2000). A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signalling. Proc Natl Acad Sci; 97:10162-10167.
    14. Bulut Y, Faure E, Thomas L, Equils O, Arditi M. (2002). Cooperation of Toll like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein a lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signalling. J Immunol; 167:987–94.
    15. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, et al. (2000). Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol; 2:346–51..
    16. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. (2003). Inhibition of IL-1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med; 197:263–8.
    17. Cao Z, Henzel WJ, GAO X. (1996). Irak: a kinase associated with the interleukin-1 receptor. Science; 271:1128–31.
    18. Choe J, Kelker MS, Wilson IA. (2005). Crystal structure of human toll like receptor 3 (TLR3) e ectodomain. Science; 309:581-585..
    19. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. (2000). Activation of the IÉ _ B kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell; 103:351–61.
    20. Doyle SE, Vaidya SA, O'Connell R, Dadgostar H, Dempsey PW, Wu T-T, et al. (2002). IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity; 7:251–63.
    21. Dunne A, Ejdeback M, Ludidi PL, O'Neill LA, Gay NJ. (2003). Structural complementarity of Toll/Interleukin1 receptor identity regions in toll-like receptors and the adaptors Mal and MyD88. J Biol Chem; 278:41443-41451.
    22. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT et al. (2003). IKKε and TBK1 are essential components of the IRF3 signalling pathway. Nat Immunol; 4:491–6.
    23. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies C, Mansell AS, Brady G, et al. (2001). Mal (MyD88-adaptor-like) is required for Toll-like receptor-4 signal transduction. Nature; 413:78–83.
    24. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. (1999). Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest; 104:271-280.
    25. Gregory M. Barton and Ruslan Medzhitov. (2003) Toll-Like Receptor Signalling Pathways. Nature immunology; 300:1524-1525.
    26. Guillot L, Medjane S, Le-Barillec K, Balloy V, Danel C, Chignard M, Si-Tahar M. (2003). Response of human pulmonary epithelial cells to LPS involves toll-like receptor 4(TLR4)-dependent signalling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem: in press.
    27. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. (2000). Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF-6). J Exp Med; 192:595–600.
    28. Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW, Smith GL, Bowie A, O'Neill LA. (2003). the poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med; 197:343-35.
    29. Hashimoto C, Hudson KL, Anderson KV. (1988).The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell; 52:269–79.
    30. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. (2001). The innate immune response to bacterial flagellin is mediated by Toll-like receptor-5. Nature; 410:1099–103.
    31. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T et al. (2003) The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol; 33:2987–97.
    32. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signalling pathway. Nat Immunol; 3:196-200
    33. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo S, Hoshino K, et al. (2002). Small antiviral compounds activate immune cells via TLR7 MyD88-dependent signalling pathway. Nat Immunol; 3:196–200.
    34. Hemmi, H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S.A. (2000). Toll-like receptor recognizes bacterial DNA. Nature; 408:740–745.
    35. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors. (2004). a: toll-like receptor 4 resides in the Golgi apparatus and Cell surface receptors Host–microbe interactions: bacteria Current Opinion in Microbiology; 7:25–32.
    36. Hornef MW, Normark BH, Vandewalle A, Normark S: Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med. (2003): 198:1225-1235.
    37. Horng T, Barton GM, Flavell RA, Medzhitov R. (2002). The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature; 420:329–33.
    38. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol. (2001):2:835–41.
    39. Hoshino K, Kaisho T, Iwabe T, Takeuchi O, Akira S. (2002). Differential involvement of IFN-γ in Toll-like receptor-stimulated dendritic cell activation. Int Immunol; 14:1225–31.
    40. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. (1999). Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol; 162:3749–52.
    41. Janssens S, Beyaert R. (2003). Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell; 11:293–302.
    42. Jiang Z, Johnson HJ, Nie H, Qin J, Bird TA, Li X. (2003). Pellino 1 is required for interleukin-1 (IL-1)-mediated signalling through its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAKtumor necrosis factor receptor-associated factor 6 (TRAF6) complex. J Biol Chem; 278:10952–6.
    43. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. (2002). Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol; 3:499.
    44. Jurk M., Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. (2002). Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R- 848. Nat. Immunol; 3:499.
    45. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu, S, Takeuchi O, Akira S. (2004). Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. (2004):5:1061–1068.
    46. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, et al. (2001). Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IRF-3 and the expression of a subset of LPS-inducible genes. J Immunol; 167:5887–94.
    47. Khan JA, Brint EK, O'Neill LA, Tong L. (2004). Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem; 279:31664-31670.
    48. Kim Y, Zhou P, Qian L, Chuang JZ, Lee J, Li C, et al. (2007). MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med; 204:2063–74.
    49. Kobayashi K, Hernandez LD, Galan JE, Janeway Jr CA, Medzhitov R, Flavell RA. (2002). IRAK-M is a negative regulator of Toll-like receptor signaling. Cell; 110:191–202.
    50. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. (2002). Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature; 416:603-607.
    51. Lemaitre B. (2004).Toll like receptor:innate immune sensors. Nature review Immunol; 4(7):521-7.
    52. Li C, Zienkiewicz J, Hawiger J. (2005). Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biol Chem; 280:26152-26159.
    53. Li S, Strelow A, Fontana EJ, Wesche H. (2002). IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci; 99:5567–72.
    54. Liberati NT, Fitzgerald KA, Kim DH, Feinbaum R, Golenbock DT, Ausubel FM. (2004). Requirement for a conserved Toll/interleukin-1 resistance domain protein in the Caenorhabditis elegans immune response. Proc Natl Acad Sci; 101:6593–8.
    55. Lomaga MA, YehWC, Sarosi I, Duncan GS, Furlonger C, Ho A, et al. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin- 1, CD40, and LPS signaling. Genes Dev; 13:1015–24.
    56. Luke AJ, O'Neill. (2003). Theraputic targeting of Toll like receptor for inflammatory and infectious disease. Current opinion in pharmacology; 3:396-403.
    57. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki. A. (2003). Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med; 198:513–520.
    58. Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature; 388:394–7.
    59. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. (1999). Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells; 4:353–62.
    60. Ohashi K, Burkart V, Flohe S, Kolb H: Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. (2000): 164:558-561.
    61. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF III. (2001). the extra domain A of Fibronectin activates Toll-like receptor 4. J Biol Chem; 276:10229-10233.
    62. O'Neill LA, Fitzgerald KA, Bowie AG. (2003). The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol; 24:286–90.
    63. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. (2003). TICAM-1an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-α induction. Nat Immunol; 4:161–7.
    64. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG (2002). Taking toll: lipid a mimetics as adjuvants and immunomodulators. Trends Microbiol; 10:S32-S37.
    65. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science; 282:2085-2088.
    66. Poltorak A, Smirnova, I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M., Galanos C, Freudenberg M., Ricciardi-Castagnoli P, Layton B, Beutler, B. (1998) . Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science; 282:2085–2088.
    67. Prince LR, Whyte MK, Saboroe L, Parker LC. (2011). the role of Toll like receptors in neutrophil activation. Current opinion in pharmacology; 11:397-403.
    68. Rifkin IR., Leadbetter EA., Busconi L, Viglianti G, Marshak-Rothstein A. (2005). Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev; 204:27–42.
    69. Sarkar SN, Smith HL, Rowe TM, Sen GC. (2003). Double-stranded RNA signalling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. J. Biol. Chem; 278:4393–4396.
    70. Sarkar, S.N., Peters, K.L., Elco, C.P., Sakamoto, S., Pal, S. and Sen, G.C. (2004). Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signalling. Nat. Struct. Mol. Biol; 11:1060–1067.
    71. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, et al. (2000). Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-γ gene induction. Immunity; 13:539–48.
    72. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R. (2000). Recognition of CpG DNA is mediated by signalling pathways dependent on the adaptor protein MyD88. Curr Biol; 10:1139–42.
    73. Schwabe RF, Seki E, Brenner DA. (2006). Toll-like receptor signalling in the liver. Gastroenterology; 130:1886–900.
    74. Seki E, Brenner DA. (2008). Toll-like receptors and adaptor molecules in liver disease: update. Hepatology; 48:322–35.
    75. Sen GC, Sarkar SN. (2005). Transcriptional signalling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev; 16: 1–14.
    76. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. (2003). Triggering the interferon antiviral response through an IKK-related pathway. Science; 300:1148–51.
    77. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature. (2002):416:750–6.
    78. Swantek JL, Tsen MF, Cobb MH, Thomas JA. (2000). IL-1 receptor associated kinase modulates host responsiveness to endotoxin. J Immunol; 164:4301–6.
    79. Syed TA. (2001). a review of the applications of imiquimod: a novel immune response modifier. Expert Opin Pharmacother; 2:877-882..
    80. Takeda K, Akira S. (2004). TLR signaling pathways. Seminar in immunology; 16:3-9.
    81. Takeda K, Akira S. (2005). Toll-like receptors in innate immunity. Int. Immunol; 17:1–14.
    82. Takeda K., Akira S. (2004). Seminars in Immunology; 16: 3–99.
    83. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, et al. (2000). Cutting edge: preferentially the R-stereoisomer of the Mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signalling pathway. J Immunol; 164:554–7.
    84. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf, JD, Zychlinsky A, Takeda K, Akira S. (2001). Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol; 13:933–940.
    85. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S. (2002). Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol; 169:10–14.
    86. Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S. (2000). Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signalling cascades. Int Immunol; 12:113–7.
    87. Toshchakov V, Jones BW, Perera PY, Thomas K, Cody MJ, Zhang S, et al. (2002). TLR4, but not TLR2, mediates IFN- γ induced STAT1 dependent gene expression in macrophages. Nat Immunol; 3: 392–8.
    88. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, Takeuchi O, Akira S. (2005). Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR) 7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med; 201:915–923.
    89. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M et al. (1999). The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature; 401:811–5.
    90. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J-I, Chen ZJ. (2001). TAK1 is an ubiquitin-dependent kinase of MKK and IKK. Nature; 412:346–51.
    91. Weaver BK, Kumar KP, Reich NC. (1998). Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA activated transcription factor DRAF1. Mol Cell Biol; 18:1359– 68.
    92. X LI et al. (2010). Cytokine; 49:1-9.
    93. Xinyan LI, Song Jiang, Richard IT. (2010). Toll like receptor in cell proliferation and survival. Cytokine; 49(1)-1-9.
    94. Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L. (2000). Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature; 408:111-115.
    95. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. (2003). Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science. 301:640–3.
    96. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, et al. (2002). Essential role of TIRAP/Mal for activation of the signalling cascade shared by TLR2 and TLR4. Nature; 420:324–9.
    97. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, et al. (2002). Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-γ promoter in the Tolllike receptor signaling. J Immunol; 169:6668–72
    98. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. (1998). Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J; 17:1087–95.
    99. Yu KY, Kwon HJ, Norman DA, Vig E, Goebl MG, Harrington MA. (2002). Cutting edge: mouse Pellino-2 modulates IL-1 and lipopolysaccharide signalling. J Immunol; 169:4075–8.
    100. Zhang G, Ghosh S. (2002). Negative regulation of toll-like receptor-mediated signalling by Tollip. J Biol Chem; 77:7059–65.

  • Downloads

  • How to Cite

    Shah, G., Patel, B., & Chorawala, M. (2014). Toll like receptors: an overview. International Journal of Pharmacology and Toxicology, 2(2), 53-61. https://doi.org/10.14419/ijpt.v2i2.3027

    Received date: 2014-06-11

    Accepted date: 2014-07-12

    Published date: 2014-07-19